Ardelyx Inc (ARDX)
6.65
+0.29
(+4.56%)
USD |
NASDAQ |
Sep 27, 16:00
6.73
+0.08
(+1.20%)
After-Hours: 20:00
Ardelyx SG&A Expense (Annual): 134.40M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 134.40M |
| December 31, 2022 | 76.60M |
| December 31, 2021 | 72.30M |
| December 31, 2020 | 33.15M |
| December 31, 2019 | 24.27M |
| December 31, 2018 | 23.72M |
| Date | Value |
|---|---|
| December 31, 2017 | 23.23M |
| December 31, 2016 | 18.73M |
| December 31, 2015 | 13.53M |
| December 31, 2014 | 7.287M |
| December 31, 2013 | 3.70M |
| December 31, 2012 | 4.031M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
24.27M
Minimum
2019
134.40M
Maximum
2023
68.14M
Average
72.30M
Median
2021
SG&A Expense (Annual) Benchmarks
| Enanta Pharmaceuticals Inc | 52.89M |
| Sage Therapeutics Inc | 274.52M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |